STM publisher Elsevier, Netherlands, has announced the acquisition of Aureus Sciences, a Paris, France, based privately held company that provides databases and information tools to pharmaceutical and biotech companies.
Formed in 2002, Aureus Sciences gathers unique and high quality quantitative biological activity data for major therapeutic drug targets. This content enables researchers to identify the most promising compounds, repurpose existing compounds and identify targets with which the new compounds might interact.
The acquisition enables the combination of high quality and deeply extracted content from both companies to launch new solutions for Elsevier's Pharmaceutical and Biotech customers. The first evidence of this will be seen early this year with the release of a new medicinal chemistry solution.
The acquisition is effective immediately and financial terms of the transaction are not being disclosed.
